These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21440548)

  • 21. Mannose-binding lectin 2 rs11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population.
    Wang PS; Kuai J; Li H; Wang CG; Shi BJ; Zhong L
    Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):282-8. PubMed ID: 27298104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection.
    Sghaier I; Zidi S; Mouelhi L; Ghazoueni E; Brochot E; Almawi WY; Loueslati BY
    Br J Biomed Sci; 2019 Jan; 76(1):35-41. PubMed ID: 30421643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between Toll-Like Receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCV.
    Mosaad YM; Metwally SS; Farag RE; Lotfy ZF; AbdelTwab HE
    Immunol Invest; 2019 Apr; 48(3):321-332. PubMed ID: 30321082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
    J Gastroenterol; 2014 Jul; 49(7):1152-62. PubMed ID: 23860735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
    Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
    Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    Wei MT; Le MH; Landis C; Trinh H; Wong G; Le A; Zhang J; Cheung R; Nguyen MH
    J Med Virol; 2021 Nov; 93(11):6257-6266. PubMed ID: 34219250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
    Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
    Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα-2a.
    Hagiwara S; Sakurai T; Takita M; Ueshima K; Minami Y; Inoue T; Yada N; Kitai S; Nagai T; Hayaishi S; Arizumi T; Nishida N; Kudo M
    Dig Dis; 2012; 30(6):561-7. PubMed ID: 23258095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
    Ghanm SE; Shebl NA; El Sayed IET; Abdel-Bary HM; Saad BF; Othman Saad W
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3203-3210. PubMed ID: 34710996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
    Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
    Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
    Senkerikova R; Frankova S; Jirsa M; Kreidlova M; Merta D; Neroldova M; Chmelova K; Spicak J; Sperl J
    PLoS One; 2019; 14(9):e0222609. PubMed ID: 31527889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.
    Matsumura H; Nirei K; Nakamura H; Higuchi T; Arakawa Y; Ogawa M; Tanaka N; Moriyama M
    World J Gastroenterol; 2013 Aug; 19(30):4887-96. PubMed ID: 23946593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.
    Guyot E; Sutton A; Rufat P; Laguillier C; Mansouri A; Moreau R; Ganne-Carrié N; Beaugrand M; Charnaux N; Trinchet JC; Nahon P
    J Hepatol; 2013 Feb; 58(2):312-8. PubMed ID: 23069476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection.
    Qi P; Wang H; Chen YM; Sun XJ; Liu Y; Gao CF
    Pathology; 2009; 41(6):555-60. PubMed ID: 19900104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea.
    Shin SP; Kim NK; Kim JH; Lee JH; Kim JO; Cho SH; Park H; Kim MN; Rim KS; Hwang SG
    World J Gastroenterol; 2015 Dec; 21(46):13064-72. PubMed ID: 26672513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variants of XRCC1 and risk of hepatocellular carcinoma in chronic hepatitis C patients.
    Arafa M; Besheer T; El-Eraky AM; Abo El-Khair SM; Elsamanoudy AZ
    Br J Biomed Sci; 2019 Apr; 76(2):64-69. PubMed ID: 31025604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.